These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6175788)

  • 1. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity.
    Golub SH; D'Amore P; Rainey M
    J Natl Cancer Inst; 1982 May; 68(5):711-7. PubMed ID: 6175788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population.
    Golub SH; Dorey F; Hara D; Morton DL; Burk MW
    J Natl Cancer Inst; 1982 May; 68(5):703-10. PubMed ID: 6175787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
    Karavodin LM; Golub SH
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J.
    Platsoucas CD; Fox FE; Oleszak E; Fong K; Nanno M; Ioannides CG; Trotta PP
    Anticancer Res; 1989; 9(4):849-58. PubMed ID: 2817813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mechanism of natural killer cytotoxicity. III. Activation of NK cells by interferon augments the lytic activity of released natural killer cytotoxic factors (NKCF).
    Wright SC; Bonavida B
    J Immunol; 1983 Jun; 130(6):2960-4. PubMed ID: 6189908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF).
    Wright SC; Bonavida B
    J Immunol; 1983 Jun; 130(6):2965-8. PubMed ID: 6189909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
    Brunda MJ; Taramelli D; Holden HT; Varesio L
    J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
    Burns GF; Triglia T; Werkmeister JA
    J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
    Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
    Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
    Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
    J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
    Koren HS; Brandt CP; Tso CY; Laszlo J
    J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of interferon in human natural killer activity against target cells infected with HSV-1.
    Bishop GA; Glorioso JC; Schwartz SA
    J Immunol; 1983 Oct; 131(4):1849-53. PubMed ID: 6194217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of interferon-alpha (MOR-22) on human NK cell activity].
    Yanagihara Y; Tochizawa S; Ishii K; Hirai Y
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):342-8. PubMed ID: 3947110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
    Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
    J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal macrophages and NK cell cytotoxicity in human systemic lupus erythematosus and the role of interferon and serum factors.
    Zippel D; Lackovic V; Kocisková D; Rovenský J; Borecký L; Stelzner A
    Acta Virol; 1989 Sep; 33(5):447-53. PubMed ID: 2483602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):528-39. PubMed ID: 6363630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons.
    Brunda MJ; Rosenbaum D
    Cancer Res; 1984 Feb; 44(2):597-601. PubMed ID: 6692364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
    Fujimiya Y; Wagner RJ; Groveman S; Sielaff K; Kohsaka T; Nakayama M
    Ther Immunol; 1995 Feb; 2(1):15-22. PubMed ID: 7553067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.